Multiple erythematous nodules with a necrotic center in a patient with acute lymphoblastic leukemia  by Yeh, Yu-Wen & Wang, Wei-Ming
at SciVerse ScienceDirect
DERMATOLOGICA SINICA 30 (2012) 117–118Contents lists availableDermatologica Sinica
journal homepage: http: / /www.derm-sinica.comRESIDENT’S FORUM
Multiple erythematous nodules with a necrotic center in a patient with acute
lymphoblastic leukemiaCase report
A Taiwanese man 20 years of age presented with neutropenic fever,
dyspnea, and generalized skin eruptions after receiving chemo-
therapy for the management of acute lymphoblastic leukemia
(Figure 1A). The chemotherapy regimen was given for 6 months
but discontinued due to the profound pancytopenia, in which the
absolute neutrophil count (ANC) was below 100/mm3. Multiple
discrete painful skin eruptions started to develop 2 months later.
The initial presentation of skin lesions was multiple tender
erythematous papules to subcutaneous nodules carrying a necroticFigure 1 (A) Generalized skin eruptions over the trunk and extremities; (B) red patches in t
progression to bullae and eschars in the end stage.
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doi:10.1016/j.dsi.2012.02.001center (Figure 1B), in which bullae and crusted ulceration devel-
oped progressively (Figures 1C and D). Skin biopsy showed
numerous acute angle branching septate hyphae within dermal
blood vessels resulting in vascular occlusion (Figures 2A and B).
Concurrently, chest radiography revealed reticulonodular opacities
in the bilateral lung. The patient was treated with oral voriconazole
200 mg twice a day and intravenous micafungin 100 mg once a day
for 3 weeks according to the results from micro-organic culture of
both sputum and skin specimen. However, the general condition
including neutropenia and dyspnea were not reversed. He eventu-
ally died due to sepsis with respiratory failure.he early stage and erythematous nodules with a necrotic center in the late stage; (C, D)
n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 (A) Ischemic degeneration in the epidermis and thrombotic dermal blood vessels were seen (hematoxylin & eosin (H&E) stain, 100); (B) numerous septate hyaline fungal
hyphae invaded dermal blood vessels (hematoxylin & eosin (H&E) stain, 400); (C) microscopic slide preparation of the fungal culture revealed Fusarium (400).
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Disseminated fusariosis.
Discussion
Both skin-tissue and sputum culture revealed the growth of Fusa-
rium spp. (Figure 2C), whereas the blood culture showed negative
ﬁnding. Fusarium is a ﬁlamentous fungus found naturally on plants
and in the soil. The most common Fusarium species associated with
human infection are F. solani, F. oxysporum, and F. moniliforme. In
immunocompetent patients, infections may develop over the skin
defect resulting from trauma, burns, insect bites, or foreign body
implantations. Disseminated fusariosis mainly occurs in severely
immunocompromised hosts and manifests cutaneous involvement
in up to 70% of cases.1 Nasal sinuses are the other source for dissem-
inated Fusarium infection. Fusariosis is one of the leading fungal
infections in victims with hematologic malignancies, preceded by
candidiasis and aspergillosis.1
Localized cutaneous infections shown in immunocompetent
patients may display various clinical manifestations including
nonspeciﬁc papules, plaques, pustules, ulcers, or cellulitis in addi-
tion to onychomycosis. The presentation of generalized erythema-
tous papulonodular lesions in a neutropenic and febrile patient not
responding to extensive antibiotic treatment is highly suggestive of
disseminated fungal infections, such as the fusariosis found in our
case. Typically, the cutaneous lesions of disseminated fusariosis
are concurrently shown at different stages of development, such
as multiple papules, subcutaneous nodules, target-like lesions,
and ecthyma gangrenosum-like lesions, where the associated
necrotic centers are related to the vascular invasion by fungi.
Hemorrhagic bullae or subcutaneous abscess may also occur.2
The histopathologic examination of skin lesions revealed acute-
angled branching and septated hyaline fungal hyphae, which
invaded dermal blood vessels and resulted in thrombosis. The
aforementioned pathologic ﬁndings are corresponding to the clin-
ical feature of necrotic centers shown in cutaneous lesions. The
histopathologic features of angioinvasion shown by Fusarium
resemble to those of aspergillus and Scedosporium, among others.
The deﬁnitive diagnosis is dependent on the isolation of organism
from skin biopsy specimen or blood culture. Different from asper-
gillosis, disseminated fusariosis can be diagnosed by blood culture
in 40% patients.1 Although our case revealed a negative result from
the blood culture, the reported rate of positive blood culture is
nearly 60% in the presence of disseminated cutaneous fusariosis.3
Fusarium species are resistant to many antifungal agents such as
itraconazole, ketoconazole, ﬂuconazole, caspofungin, and micafun-
gin.4 Therefore, thestandard treatment isnotwelldocumented.4 Lipo-
somal amphotericin is usually the treatment of choice and thecombination with voriconazole has been reported as a successful
treatment for the resistant strain.4 Granulocyte colony-stimulating
factor and granulocyte-macrophage colony-stimulating factor may
exhibit clinical beneﬁts by reducing the duration of neutropenia.
However, the mortality rate in refractory neutropenic patients is
nearly 100%.5
Prolonged neutropenia, acute graft-versus-host disease, gluco-
corticoid administration, and bone marrow transplantation from
an human leukocyte antigen (HLA)-mismatched donor are the
risk factors for disseminated fusariosis.5 Disseminated fusariosis
is a life-threatening disease whose prognosis is mostly dependent
on the immunity of patients. Unfortunately, the outcome of neu-
tropenic patients with fungemia is still poor despite the avail-
ability of new antifungal agents. Cutaneous lesions usually
precede fungemia and may serve as clues for the early detection
of disseminated fusariosis in most patients.3 Therefore, dermatol-
ogists should be aware of these characteristic clinic features and
provide adequate management in the early stage for patients
who are immunocompromised.
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